VisMederi Group

From kit design and manufacturing to biological sample management and laboratory testing, VisMederi offers a fully integrated solution for clinical trials and research programs worldwide.

Building on its long-standing experience in vaccine development and immunological testing, VisMederi now supports sponsors, CROs, and clinical sites from the earliest operational stages of a study, providing expertise that extends well beyond laboratory analysis. The service covers the entire lifecycle of sample collection kits, including customized kit design, component sourcing, reagent and buffer preparation, kit assembly, labeling, packaging, and quality documentation, all performed in compliance with international regulatory requirements.

A key strength of the offering is VisMederi’s ability to coordinate complex global logistics operations. The company manages the distribution of kits to clinical sites worldwide, temperature-controlled shipment of biological samples, customs clearance activities, and sample reconciliation processes, ensuring full traceability and operational consistency throughout the study.

To support standardized procedures across multiple sites, VisMederi also developscustomized Laboratory Manuals and provides on-site training for clinical personnel, including specialized instruction on PBMC isolation and storage procedures, which are critical for many immunology and vaccine studies.

The workflow supported by VisMederi spans every step leading up to laboratory analysis, from initial protocol review and logistics planning through kit deployment, sample collection, transportation, and laboratory receipt. Upon request, VisMederi can also perform immunological and vaccine evaluation testing, offering sponsors a seamless transition from sample collection to data generation.

Read more: https://www.vismederiholding.com/vismederi-expands-its-service-portfolio-with-end-to-end-sample-kit-management/

VisMederi and CEVAC, a Belgian vaccine research center comprising a Clinical Trial Unit and an Immunomonitoring Laboratory, have signed a Memorandum of Understanding (MoU) to strengthen their collaboration in vaccine clinical trials, a core area of expertise for both organi-zations.

The agreement represents a concrete step toward a more integrated European collaboration model, fostering closer cooperation between clinical research, laboratory science, and opera-tional excellence to accelerate vaccine development programs.
The partnership is founded on a shared commitment to advancing vaccine research and public health. By combining complementary expertise, infrastructure, and international networks, VisMederi and CEVAC aim to support vaccine developers with high-quality scientific and opera-tional services, with particular attention to emerging infectious diseases and future pandemic preparedness.

Together, the two organizations will be able to provide a comprehensive solution across the vaccine clinical development pathway, from clinical site management and participant recruit-ment to sample processing, immunological and bioanalytical testing, data management, and scientific support throughout the entire clinical trial process.
For VisMederi, the partnership further expands its network of international collaborations and strengthens its ability to support vaccine developers through increasingly comprehensive and integrated solutions. In a rapidly evolving global health landscape, strategic partnerships are essential to advancing innovation and responding effectively to emerging public health challenges.

As Alessandro Manenti, Chief Development Officer at VisMederi, highlighted:
"This agreement creates new opportunities to develop meaningful synergies between our organizations and expand the range of services we can offer to vaccine developers. By combining our respective expertise, we can contribute more effectively to the advancement of innovative vaccine programs and support global efforts to improve preparedness against emerging infectious diseases."

VisMederi and KingMylab have announced the signing of a strategic collaboration agreement aimed at strengthening testing and analytical services for vaccine and biologics clinical trials. The partnership combines KingMylab's expertise in central laboratory services for clinical research with VisMederi's extensive experience in vaccine evaluation, bioanalytical assay development, and the generation of scientific data supporting clinical development programs.

As the global healthcare community continues to face emerging infectious disease threats and increasing pressure to accelerate the development of innovative vaccines, access to reliable, standardized, and internationally compliant testing services has become more critical than ever.

The partnership will focus particularly on supporting Multi-Regional Clinical Trials (MRCTs) by implementing harmonized processes and comparable testing methodologies across participating study sites worldwide. This approach will ensure high-quality, consistent, and globally acceptable data, facilitating international regulatory pathways and accelerating the development of innovative vaccines and biologics.
This partnership marks an important milestone in VisMederi's international growth strategy. By combining VisMederi's scientific expertise with KingMylab's strong operational presence in Asia, we will be able to provide our partners with increasingly integrated, high-value solutions for the global development of vaccines.



VisMederi e KingMylab hanno annunciato la firma di un accordo di collaborazione strategica volto a rafforzare le attività di testing e analisi per studi clinici su vaccini e prodotti biologici. La partnership unirà l'esperienza di KingMylab nei servizi di laboratorio centrale per la ricerca clinica con le competenze di VisMederi nella valutazione immunologica dei vaccini, nello sviluppo di saggi bioanalitici e nella generazione di dati scientifici a supporto dello sviluppo clinico.

In un contesto globale caratterizzato dalla continua emergenza di nuove minacce infettive e dalla crescente necessità di accelerare lo sviluppo di vaccini innovativi, la disponibilità di servizi analitici affidabili, standardizzati e conformi agli standard internazionali rappresenta un elemento fondamentale per il successo dei programmi clinici.
La collaborazione tra le due realtà punta in particolare a rafforzare il supporto agli studi clinici multinazionali (MRCT, Multi-Regional Clinical Trials), attraverso l'implementazione di processi armonizzati e metodologie comparabili tra i diversi centri coinvolti. L'obiettivo è garantire la massima qualità e comparabilità dei dati generati, facilitando l'accettazione internazionale dei risultati e contribuendo ad accelerare lo sviluppo di nuovi vaccini e prodotti biologici.

Questa partnership rappresenta un importante passo avanti nella nostra strategia di espansione internazionale. Combinando le competenze scientifiche di VisMederi con la forte presenza operativa di KingMylab nel mercato asiatico, saremo in grado di offrire ai nostri partner soluzioni sempre più integrate e di elevato valore scientifico per lo sviluppo globale di vaccini.

Emanuele Montomoli joined InBlu2000 to discuss the latest updates on the Hantavirus case and the negative test results reported for the four individuals monitored in Italy.

The interview focused on health surveillance, prevention, and the importance of clear, data-driven scientific communication.

🎙️ Listen to the full interview: https://www.play2000.it/detail/140?episode_id=33798&season_id=908



Emanuele Montomoli è intervenuto ai microfoni di InBlu2000 per commentare gli ultimi aggiornamenti sul caso Hantavirus e la situazione dei test effettuati in Italia, risultati negativi sulle quattro persone monitorate.

Un approfondimento dedicato ai temi della sorveglianza sanitaria, della prevenzione e dell’importanza di una comunicazione scientifica chiara e basata sui dati.

🎙️ Ascolta l’intervento completo: https://www.play2000.it/detail/140?episode_id=33798&season_id=908

VisMederi is collaborating with Osivax on research activities spanning from early-stage research to preclinical development and clinical studies in the field of respiratory infections.

This collaboration further reinforces VisMederi’s role in supporting vaccine innovation through high-quality and reliable scientific work.

VisMederi collabora con Osivax in attività di ricerca che spaziano dalla fase iniziale allo sviluppo preclinico e agli studi clinici nel campo delle infezioni respiratorie.

Questa collaborazione rafforza ulteriormente il ruolo di VisMederi nel sostenere l'innovazione nel campo dei vaccini attraverso un lavoro scientifico affidabile e di alta qualità.